Dysbiosis of the Skin and Mucosal Mycobiome in Psoriasis Patients Treated with IL-23 Inhibitors

Psoriasis is a chronic inflammatory skin disease characterized by immune dysregulation, where treatments like IL-23 inhibitors have shown promising results. However, the broader effects of such treatments on the skin’s microbial ecosystem, particularly the mycobiome (the fungal component of the…








